Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17440232 | 0.73 | LMNA (0.37) | ALDH1A1KDM4ERAB9AKMT2AMEN1 | |
| SCHEMBL29034266 | 0.72 | GBA1 (0.46) | ALDH1A1KDM4ERAB9ANPC1KMT2A | |
| SCHEMBL12640161 | 0.68 | METAP1 (0.44) | RAB9ANPC1KMT2ASMN1; SMN2 | |
| SCHEMBL1875012 | 0.68 | LMNA (0.37) | ALDH1A1KDM4ERAB9A | |
| SCHEMBL12640160 | 0.67 | NPC1 (0.38) | ALDH1A1KDM4ERAB9ANPC1KMT2A | |
| SCHEMBL2898172 | 0.67 | KDM4E (0.36) | ALDH1A1KDM4E | |
| SCHEMBL1648161 | 0.66 | PTGDR2 (0.36) | ALDH1A1KDM4EKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL1878926 | 0.66 | ADRA2A (0.33) | ALDH1A1KDM4ERAB9ANPC1KMT2A | |
| SCHEMBL17440276 | 0.65 | LMNA (0.35) | ALDH1A1KDM4E | |
| SCHEMBL2191688 | 0.64 | RAB9A (0.37) | ALDH1A1KDM4ERAB9AKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105564-A1 | THIENYLPYRIDYLCARBOXAMIDES | BAYER CROPSCIENCE AG (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-1965640-A2 | THIENYLPYRIDYL CARBOXAMIDES | Bayer CropScience AG (DE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007068374-A2 | THIENYLPYRIDYL CARBOXAMIDES | BAYER CROPSCIENCE AG (DE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105564-A1 | THIENYLPYRIDYLCARBOXAMIDES | TPI1, PGLS, TYMS | ALDH1A1 444/4885KDM4E 1321/4885RAB9A 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.